739P Patient preference for subcutaneous nivolumab (NIVO) with/without recombinant human hyaluronidase PH20 (rHuPH20) vs intravenous NIVO: An exploratory analysis of a phase I/II pharmacokinetic multi-tumor study

Abstract

Subcutaneous (SC) NIVO co-formulated with rHuPH20 may benefit patients (pts), healthcare practitioners (HCPs), and healthcare resource utilization. In the phase 1/2 international multi-tumor CheckMate 8KX study, the pharmacokinetics and exposures of SC NIVO + rHuPH20 were characterized across multiple doses and treatment was well tolerated. Here, we present pt preference for SC vs intravenous (IV) NIVO.